NCT06613360 - A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 21, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

SLESLE (Systemic Lupus)

Interventions

DRUG

CLN-978

Specified dose on specified days

Trial Locations (12)

10032

RECRUITING

Cullinan Investigative Site, New York

14642

RECRUITING

Cullinan Investigative Site, Rochester

32808

RECRUITING

Cullinan Investigative Site, Orlando

52242

RECRUITING

Cullinan Investigative Site, Iowa City

75093

RECRUITING

Cullinan Investigative Site, Plano

77598

RECRUITING

Cullinan Investigative Site, Webster

84101

RECRUITING

Cullinan Investigative Site, Salt Lake City

85392

RECRUITING

Cullinan Investigative Site, Avondale

85704

RECRUITING

Cullinan Investigative Site, Tucson

Unknown

RECRUITING

Cullinan Investigative Site, Victoria Park

RECRUITING

Arensia Research Clinic, Tbilisi

RECRUITING

Arensia Research Clinic, Chisinau